Background: To investigate whether flow-mediated dilation (FMD) impairment, which precedes overt atherosclerosis, is associated with silent myocardial ischemia (SMI) and asymptomatic coronary artery disease (CAD) in type 2 diabetes.
Methods: Forearm FMD was measured by ultrasonography in 25 healthy control, 30 non-diabetic overweight or obese patients and 118 asymptomatic type 2 diabetic patients with a high cardiovascular risk profile. SMI (abnormal stress myocardial scintiscan and/or stress dobutamine echocardiogram) and CAD (coronary angiography in the patients with SMI) were assessed in the diabetic cohort.
Results: FMD was lower in diabetic patients (median 0.61% (upper limits of first and third quartiles -1.22;3.2)) than in healthy controls (3.95% (1.43;5.25), p < 0.01) and overweight/obese patients (4.25% (1.74;5.56), p < 0.01). SMI was present in 60 diabetic patients, including 21 subjects with CAD. FMD was lower in patients with SMI than in those without (0.12% (-2.3;1.58) vs 1.64% (0;3.69), p < 0.01), with a higher prevalence of paradoxical vasoconstriction (50.0% vs 29.3%, p < 0.05). FMD was also lower in patients with than without CAD (-1.22% (-2.5;1) vs 1.13% (-0.4;3.28), p < 0.01; paradoxical vasoconstriction 61.9% vs 34.4%, p < 0.05). Logistic regression analyses considering the parameters predicting SMI or CAD in univariate analyses with a p value <0.10 showed that paradoxical vasoconstriction (odds ratio 2.7 [95% confidence interval 1.2-5.9], p < 0.05) and nephropathy (OR 2.6 [1.2-5.7], p < 0.05) were independently associated with SMI; and only paradoxical vasoconstriction (OR 3.1 [1.2-8.2], p < 0.05) with CAD. The negative predictive value of paradoxical vasoconstriction to detect CAD was 88.7%.
Conclusions: In diabetic patients, FMD was independently associated with SMI and asymptomatic CAD.
Trial Registration: Trial registration number NCT00685984.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901336 | PMC |
| http://dx.doi.org/10.1186/1475-2840-13-20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.
JAMA Netw Open
January 2025
Healthcare Transformation Institute, Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Importance: Adherence to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is important for their effectiveness. Discontinuation and reinitiation patterns are not well understood.
Objective: To describe rates of and factors associated with discontinuation and subsequent reinitiation of GLP-1 RAs among adults with overweight or obesity.
Sarcopenia in independent oldest-old individuals treated for diabetes, with or without metformin: a case-control study.
Acta Diabetol
January 2025
Discipline of Geriatrics and Gerontology, Paulista School of Medicine, Federal University of São Paulo, Rua dos Otonis, 863, Vila Clementino, São Paulo, SP, ZIP CODE 04025-002, Brazil.
Background: Sarcopenia is a common condition in the elderly, especially in diabetics (DM). Metformin (MTF), known to reduce glucose levels, can also be a therapeutic intervention in age-related diseases, although it may contribute to muscle loss.
Objectives: To compare the prevalence of sarcopenia among elderly people treated for DM, with or without MTF, and non-diabetic patients (NDM) and evaluate whether there is an association between the use of MTF and the development of sarcopenia.
Time to change guidelines? Suboptimal glycemic control measures by CGM associated with cystic fibrosis exacerbations despite adequate HbA1c.
Acta Diabetol
January 2025
Endocrinology Department, University Hospital La Paz, Madrid, Spain.
Application of novel strategies in chronic wound management with focusing on pressure ulcers: new perspective.
Arch Dermatol Res
January 2025
Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran.
Invading blood cells, extracellular tissue, and soluble mediators all play important roles in the wound-healing process. There is a substantial global burden of disease and mortality attributable to skin defects that do not heal. About 1% to 2% of the population in industrialized nations suffers from chronic wounds that don't heal, despite healthcare breakthroughs; this condition is very costly, costing about $25 billion each year in the US alone.
View Article and Find Full Text PDFRevealing the promising era of silk-based nanotherapeutics: a ray of hope for chronic wound healing treatment.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, Pushp Vihar, New Delhi, 110017, India.
Chronic wounds significantly contribute to disability and affect the mortality rate in diabetic patients. In addition, pressure ulcers, diabetic foot ulcers, arterial ulcers, and venous ulcers pose a significant health burden due to their associated morbidity and death. The complex healing process, environmental factors, and genetic factors have been identified as the rate-limiting stages of chronic wound healing.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!